Tumor angiogenesis in chronic pancreatitis and pancreatic adenocarcinoma: Impact of K-ras mutations

Pancreas

Volumn 20, Issue 3, 2000, Pages 248-255

  Banerjee, Sushanta K ^a   Zoubine, Mikhail N ^a   Mullick, Monalisa ^b   Weston, Allan P ^a   Cherian, Rachel ^a   Campbell, Donald R ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Chronic pancreatitis; Enriched nested polymerase chain reaction restriction fragment length polymorphism; Factor VIII related antigen; K ras oncogene; Pancreatic adenocarcinoma; Tumor angiogenesis

Indexed keywords

VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; MIDDLE AGED; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PANCREATITIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; VON WILLEBRAND FACTOR;

EID: 0034064099     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200004000-00005     Document Type: Article

References (66)

1. Gordis L, Gold EB. Epidemiology and etiology of pancreatic cancer. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The pancreas: biology, pathobiology, and disease. New York: Raven Press, 1993:837-55.
2. Landis SH, Murry T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
3. Mangray S, King TC. Molecular pathobiology of pancreatic adenocarcinoma. Front Biosci 1998;3:D1148-D1160.
4. Perugini RA, McDade TP, Vittimberga FJJ, Callery MP. The molecular and cellular biology of pancreatic cancer. Crit Rev Eukaryot Gene Expr 1998;8:377-93.
5. Dugan MC, Sarkar FH. Current concepts in pancreatic cancer: symposium summary. Pancreas 1998;17:325-33.
6. Moossa AR. Tumors of the pancreas. In: Moossa AR, Schimpff MC, Robson M, eds. Comprehensive textbook of oncology. Baltimore: Williams & Wilkins, 1991:958-88.
7. Barkin JS, Campbell DR. Serum marker for pancreatic carcinoma. Contemp Gastro 1992;5:10-22.
8. Banerjee SK, Makdisi WF, Weston AP, Campbell DR. A two-step enriched-nested PCR technique enhances sensitivity for detection of codon 12 K-ras mutations in pancreatic adenocarcinoma. Pancreas 1997;15:16-24.
9. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433-7.
10. Fernandez E, La Vecchia C, Porta M. Pancreatitis and the risk of pancreatic cancer. Pancreas 1995;11:185-9.
11. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic. Gastroenterology 1995;109:247-51.
12. Castleman B, Scully R, McNeely BU. Case records of the Massachusetts General Hospital, Case 25-1972. N Engl J Med 1972;286: 1353-6.
13. Folkman J. Fighting cancer by attacking its blood supply. Sci Am 1996;275:150-4.
14. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991;22:339-47.
15. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
16. Folkman J, Klagsburn M. Angiogenic factors. Science 1987;235: 442-7.
17. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 1992;13:18-32.
18. Risau W. What, if anything, is an angiogenic factor? Cancer Metastasis Rev 1996;15:149-51.
19. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996;15:165-76.
20. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 1997;272: 27509-12.
21. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
22. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
23. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997;90:3322-31.
24. Kerbel RS, Viloria-Petit A, Okada F, Rak J. Establishing a link between oncogenes and tumor angiogenesis. Mol Med 1998;4: 286-95.
25. Chu TM. Molecular diagnosis of pancreas carcinoma. J Clin Lab Anal 1997;11:225-31.
26. Pearson AS, Bouvet M, Evans DB, Roth JA. Gene therapy and pancreatic cancer. Front Biosci 1998;3:E230-E237.
27. Fujimoto K, Hosotani R, Wada M, et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998;34:1439-47.
28. Longnecker DS, Terhune PG. What is the true rate of K-ras mutation in carcinoma of the pancreas? [editorial]. Pancreas 1998; 17:323-4.
29. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998;34: 337-40.
30. Pitkaranta P, Kivisaari L, Nordling S, Nuutinen P, Schroeder T. Vascular changes of chronic pancreatic ducts and vessels in acute necrotizing and in chronic pancreatitis in humans. Int J Pancreatol 1991;8:13-22.
31. Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki JR. Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas 1999;18: 96-103.
32. Mitchell ML, Carney CN. Cytologic criteria for the diagnosis of pancreatic carcinoma. Am J Clin Pathol 1985;83:171-6.
33. Lankisch PG, Bank PA. Pancreatitis. Berlin, Heidelberg, New York: Springer-Verlag, 1997.
34. Banerjee SK, Makdisi WF, Weston AP, Mitchell SM, Campbell DR. Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification. Biotechniques 1995;18:768-71.
35. Banerjee SK, Campbell DR, Weston AP, Banerjee DK. Biphasic estrogen response on bovine adrenal medulla capillary endothelial cell adhesion, proliferation and tube formation. Mol Cell Biochem 1997;177:97-105.
36. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972;48:347-56.
37. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-61.
38. Banerjee SK, Sarkar DK, Weston AP, De A, Campbell DR. Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 1997;18:1155-61.
39. Bos JL. ras oncogenes in human cancer: a review [published erratum appears in Cancer Res 1990;50:1352]. Cancer Res 1989;49: 4682-9.
40. Wilentz RE, Chung CH, Sturm PD, et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998;82:96-103.
41. Dergham ST, Dugan MC, Kucway R, et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 1997;21:127-43.
42. Caldas C. Molecular assessment of cancer. BMJ 1998;316:1360-3.
43. Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995;18:1-6.
44. Yanagisawa A, Ohtake K, Ohashi K, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993;53:953-6.
45. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
46. Uehara H, Nakaizumi A, Baba M, et al. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. Am J Gastroenterol 1996;91:1616-21.
47. Rivera JA, Rall CJ, Graeme-Cook F, et al. Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. Surgery 1997;121:42-9.
48. Kondo H, Sugano K, Fukayama N, et al. Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 1997;79:900-5.
49. Watanabe H, Yamaguchi Y, Ha A, et al. Quantitative determination of K-ras mutations in pancreatic juice for diagnosis of pancreatic cancer using hybridization protection assay. Pancreas 1998;17:341-7.
50. Berndt C, Haubold K, Wenger F, et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem 1998;44:2103-7.
51. Tabata T, Fujimori T, Maeda S, Yamamoto M, Saitoh Y. The role of Ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Int J Pancreatol 1993;14:237-44.
52. Hsiang D, Friess H, Buchler MW, Ebert M, Butler J, Korc M. Absence of K-ras mutations in the pancreatic parenchyma of patients with chronic pancreatitis. Am J Surg 1997;174:242-6.
53. Orth M, Gansauge F, Gansauge S, Beger HG, Adler G, Schmid RM. K-ras mutations at codon 12 are rare events in chronic pancreatitis. Digestion 1998;59:120-4.
54. Yamada T, Nakamori S, Ohzato H, et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998;4:1527-32.
55. O'Mahony CA, Albo D, Tuszynski GP, Berger DH. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells. Surgery 1998;124:388-93.
56. O'Mahony CA, Seidel A, Albo D, Chang H, Tuszynski GP, Berger DH. Angiostatin generation by human pancreatic cancer. J Surg Res 1998;77:55-8.
57. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995;14:263-77.
58. Mulcahy HE, Lyautey J, Lederrey C, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998;4:271-5.
59. Okada F, Rak JW, Croix BS, et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998;95:3609-14.
60. Jones MK, Sarfeh IJ, Tarnawski AS. Induction of in vitro angiogenesis in the endothelial-derived cell line, EA hy926, by ethanol is mediated through PKC and MAPK. Biochem Biophys Res Commun 1998;249:118-23.
61. Casey G, Yamanaka Y, Friess H, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
62. Gansauge S, Schmid RM, Muller J, Adler G, Mattfeldt T, Beger HG. Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations. Br J Surg 1998;85: 337-40.
63. Muller J, Gansauge S, Schmid R, Gansauge F, Adler G, Beger HG. [p53 but not K-ras mutations can be found in chronic pancreatitis]. Langenbecks Arch Chir Suppl Kongressbd 1997;114:715-8.
64. Shimoyama S, Gansauge F, Gansauge S, Negri G, Oohara T, Beger HG. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 1996;56:2703-6.
65. Fontanini G, Boldrini L, Calcinai A, et al. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res 1999;5:155-61.
66. Dillon DA, Howe CL, Bosari S, Costa J. The molecular biology of breast cancer: accelerating clinical applications. Crit Rev Oncog 1998;9:125-40.